Skip to content
Home/Companies/Pharma/Synthon
SY

Synthon

Pharma·Netherlands·Exited 2024·Held 5yr

Synthon is a healthcare company, headquartered in Netherlands.

Entry
2019
Hold
5yr
Exit
2024
Est. EV
–

Who owns Synthon?

Synthon was owned by BC Partners through BC European Capital X (2018 vintage) from 2019 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

BC Partners
Investor
BC Partners
BC European Capital X · 2018 · Buyout

Key facts

HQNetherlands
SectorHealthcare
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from BC European Capital X

Other portfolio companies in the same fund.

IMA
Exited 2024
IndustrialsItaly· 2020
to
Keesing
Active
TMTNetherlands· 2020
Women's Care Enterprises
Active
HealthcareUnited States· 2020
GardaWorld
Exited 2024
Business ServicesCanada· 2019
to
OneAdvanced
Active
SoftwareUK· 2019
CeramTec
Exited 2022
IndustrialsGermany· 2018
to

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Delpharm
Active
SocadifFrance
Laboratoires Delbert
Active
SocadifFrance
IRAB
Active
ARCHIMEDSpain· 2026
Dec Group
Active
capitonSwitzerland· 2025
Essential Pharma
Active
Penta CapitalUK· 2025
Forth Therapeutics
Active
Old College CapitalUK· 2025
Data refreshed weekly · Sourced from public filings